You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 19, 2024

SANCTURA XR Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Sanctura Xr, and when can generic versions of Sanctura Xr launch?

Sanctura Xr is a drug marketed by Allergan and is included in one NDA.

The generic ingredient in SANCTURA XR is trospium chloride. There are sixteen drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the trospium chloride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Sanctura Xr

A generic version of SANCTURA XR was approved as trospium chloride by GLENMARK GENERICS on August 13th, 2010.

  Try a Trial

Drug patent expirations by year for SANCTURA XR
Recent Clinical Trials for SANCTURA XR

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Neil M. ResnickPhase 4
National Institute on Aging (NIA)Phase 4
Karuna TherapeuticsPhase 1

See all SANCTURA XR clinical trials

Paragraph IV (Patent) Challenges for SANCTURA XR
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
SANCTURA XR Extended-release Capsules trospium chloride 60 mg 022103 1 2009-03-02

US Patents and Regulatory Information for SANCTURA XR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan SANCTURA XR trospium chloride CAPSULE, EXTENDED RELEASE;ORAL 022103-001 Aug 3, 2007 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for SANCTURA XR

See the table below for patents covering SANCTURA XR around the world.

Country Patent Number Title Estimated Expiration
European Patent Office 1680110 FORME DOSIFIEE QUOTIDIENNE DE TROSPIUM (ONCE DAILY DOSAGE FORMS OF TROSPIUM) ⤷  Try a Trial
European Patent Office 2210605 Forme dosifiée quotidienne de trospium (Once daily dosage forms of trospium) ⤷  Try a Trial
Australia 2004289223 Once daily dosage forms of trospium ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.